Chulay J D, Anzeze E M, Koech D K, Bryceson A D
Trans R Soc Trop Med Hyg. 1983;77(5):717-21. doi: 10.1016/0035-9203(83)90213-4.
Cutaneous leishmaniasis caused by Leishmania aethiopica usually responds poorly to conventional doses of pentavalent antimonial drugs. We treated three patients with cutaneous leishmaniasis acquired in Kenya, presumed or documented to be caused by L. aethiopica, with intravenous sodium stibogluconate, 18 to 20 mg Sb/kg body-weight twice daily for 30 days. All patients had a good response to treatment, with disappearance of parasites from skin smears and cultures after 14 to 27 days, clinical healing of the lesions, and no recurrence during a three to 18-month follow-up. Side effects of treatment were minor. We conclude that this high dose sodium stibogluconate regimen is safe and effective for treating cutaneous leishmaniasis caused by L. aethiopica in Kenya.
由埃塞俄比亚利什曼原虫引起的皮肤利什曼病通常对常规剂量的五价锑剂反应不佳。我们用静脉注射葡萄糖酸锑钠治疗了三名在肯尼亚感染皮肤利什曼病的患者，推测或确诊为由埃塞俄比亚利什曼原虫引起，剂量为每日两次，18至20毫克锑/千克体重，共30天。所有患者对治疗反应良好，14至27天后皮肤涂片和培养物中寄生虫消失，病变临床愈合，在3至18个月的随访中无复发。治疗的副作用较小。我们得出结论，这种高剂量葡萄糖酸锑钠方案对于治疗肯尼亚由埃塞俄比亚利什曼原虫引起的皮肤利什曼病是安全有效的。
